Filtered By:
Drug: Rituxan
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 265 results found since Jan 2013.
B-cell reconstitution is associated with COVID-19 booster vaccine responsiveness in previously seronegative rituximab treated patients
CONCLUSION: Detectable B-cells and longer time from last rituximab exposure were associated with the development of anti-SARS-CoV-2 spike protein antibodies following the booster vaccine. These findings should be considered in timing boosters in rituximab-treated patients.PMID:36521910 | DOI:10.3899/jrheum.220475
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Kaitlin Schultz Deanna Jannat-Khah Robert Spiera Source Type: research
Oral antiviral treatment for COVID-19 in patients with systemic autoimmune rheumatic diseases
CONCLUSION: This data argues in favor of a favorable outcome and acceptable safety profile of the two oral antiviral therapies among a high-risk SARD population. However, cases of COVID-19 rebound are being increasingly identified. These findings call for continuous surveillance in order to capture the realworld efficacy and safety profiles in our subpopulations of interest.PMID:36521909 | DOI:10.3899/jrheum.221014
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Nafsika Gerolymatou Athanasios-Dimitrios Bakasis Paraskevi V Voulgari Panayiotis G Vlachoyiannopoulos Source Type: research
B-cell reconstitution is associated with COVID-19 booster vaccine responsiveness in previously seronegative rituximab treated patients
CONCLUSION: Detectable B-cells and longer time from last rituximab exposure were associated with the development of anti-SARS-CoV-2 spike protein antibodies following the booster vaccine. These findings should be considered in timing boosters in rituximab-treated patients.PMID:36521910 | DOI:10.3899/jrheum.220475
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Kaitlin Schultz Deanna Jannat-Khah Robert Spiera Source Type: research
Oral antiviral treatment for COVID-19 in patients with systemic autoimmune rheumatic diseases
CONCLUSION: This data argues in favor of a favorable outcome and acceptable safety profile of the two oral antiviral therapies among a high-risk SARD population. However, cases of COVID-19 rebound are being increasingly identified. These findings call for continuous surveillance in order to capture the realworld efficacy and safety profiles in our subpopulations of interest.PMID:36521909 | DOI:10.3899/jrheum.221014
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Nafsika Gerolymatou Athanasios-Dimitrios Bakasis Paraskevi V Voulgari Panayiotis G Vlachoyiannopoulos Source Type: research
B-cell reconstitution is associated with COVID-19 booster vaccine responsiveness in previously seronegative rituximab treated patients
CONCLUSION: Detectable B-cells and longer time from last rituximab exposure were associated with the development of anti-SARS-CoV-2 spike protein antibodies following the booster vaccine. These findings should be considered in timing boosters in rituximab-treated patients.PMID:36521910 | DOI:10.3899/jrheum.220475
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Kaitlin Schultz Deanna Jannat-Khah Robert Spiera Source Type: research
Oral antiviral treatment for COVID-19 in patients with systemic autoimmune rheumatic diseases
CONCLUSION: This data argues in favor of a favorable outcome and acceptable safety profile of the two oral antiviral therapies among a high-risk SARD population. However, cases of COVID-19 rebound are being increasingly identified. These findings call for continuous surveillance in order to capture the realworld efficacy and safety profiles in our subpopulations of interest.PMID:36521909 | DOI:10.3899/jrheum.221014
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Nafsika Gerolymatou Athanasios-Dimitrios Bakasis Paraskevi V Voulgari Panayiotis G Vlachoyiannopoulos Source Type: research
B-cell reconstitution is associated with COVID-19 booster vaccine responsiveness in previously seronegative rituximab treated patients
CONCLUSION: Detectable B-cells and longer time from last rituximab exposure were associated with the development of anti-SARS-CoV-2 spike protein antibodies following the booster vaccine. These findings should be considered in timing boosters in rituximab-treated patients.PMID:36521910 | DOI:10.3899/jrheum.220475
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Kaitlin Schultz Deanna Jannat-Khah Robert Spiera Source Type: research
Oral antiviral treatment for COVID-19 in patients with systemic autoimmune rheumatic diseases
CONCLUSION: This data argues in favor of a favorable outcome and acceptable safety profile of the two oral antiviral therapies among a high-risk SARD population. However, cases of COVID-19 rebound are being increasingly identified. These findings call for continuous surveillance in order to capture the realworld efficacy and safety profiles in our subpopulations of interest.PMID:36521909 | DOI:10.3899/jrheum.221014
Source: J Rheumatol - December 15, 2022 Category: Rheumatology Authors: Nafsika Gerolymatou Athanasios-Dimitrios Bakasis Paraskevi V Voulgari Panayiotis G Vlachoyiannopoulos Source Type: research
Relapses of Immune Thrombocytopenia after the second and booster doses of BNT162b2 Vaccine
We present here a 65-year-old male patient known for immune thrombocytopenic purpura (ITP) and fluctuating platelet count who experienced a severe exacerbation of thrombocytopenia following BNT162b2 COVID-19 vaccination. One month after the second dose he presented petechiae and asthenia with isolated thrombocytopenia (platelet count: 3 x 109/L). He recovered after a 4-day course of intravenous corticosteroid treatment and intravenous immunoglobulin therapy. Eight months later his platelet count was within the normal ranges and he received a booster dose of vaccine after pre-medication with prednisone. Eight days later his...
Source: Acta Haematologica - November 3, 2022 Category: Hematology Authors: Maja Ratajczak-Enselme Guy-Cl ébert Mutoni Jules Demeules Laurence Favet Kuntheavy Ing Lorenzini Source Type: research
Chronic cold agglutinin disease after a third COVID-19 mRNA vaccination
Int J Hematol. 2022 Oct 29. doi: 10.1007/s12185-022-03480-z. Online ahead of print.ABSTRACTCOVID-19 mRNA vaccines manufactured by Pfizer-BioNTech and Moderna have been approved in many countries, and have been administered since 2020. Recent reports of mRNA vaccination exacerbating autoimmune hematologic disorders, such as immune thrombocytopenia or autoimmune hemolytic anemia, have caught the attention of the general public, resulting in alarm over the risks of serious consequences. Meanwhile, in very rare cases, vaccination was reported to trigger new onset of hemolytic anemia. However, it remains unknown whether this wa...
Source: International Journal of Hematology - October 30, 2022 Category: Hematology Authors: Yutaro Suzuki Teruo Shiba Source Type: research
